Comment on : Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
| Errataetall: |
CommentOn: Int Immunopharmacol. 2021 Jun;95:107522. - PMID 33735712 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
International immunopharmacology - 102(2022) vom: 30. Jan., Seite 107693 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashemian, Seyed MohammadReza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.12.2021 Date Revised 21.12.2022 published: Print-Electronic CommentOn: Int Immunopharmacol. 2021 Jun;95:107522. - PMID 33735712 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2021.107693 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327643307 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327643307 | ||
| 003 | DE-627 | ||
| 005 | 20231225201236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2021.107693 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327643307 | ||
| 035 | |a (NLM)34217670 | ||
| 035 | |a (PII)S1567-5769(21)00329-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hashemian, Seyed MohammadReza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comment on |b Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Int Immunopharmacol. 2021 Jun;95:107522. - PMID 33735712 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 700 | 1 | |a Khoundabi, Batoul |e verfasserin |4 aut | |
| 700 | 1 | |a Velayati, Ali Akbar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 102(2022) vom: 30. Jan., Seite 107693 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2022 |g day:30 |g month:01 |g pages:107693 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2021.107693 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2022 |b 30 |c 01 |h 107693 | ||